Taking in consideration all these functions, specific and non-specific Bcl-xL inhibitors have been developed and several studies reported that interfering with Bcl-xL activity represents a valid approach to enhance the propensity of cancer cells to die [22, 23]. Here, BCL2L1 is linked to cancer.